NIAID Site Search

Lenette Lu, M.D., Ph.D., of the Massachusetts General Hospital K08 sample application

Last Reviewed: March 31, 2025

Sample grant application from Stephen Dewhurst, Ph.D., for exploratory with possible transition to expanded development grant (R21/R33).

Last Reviewed: April 21, 2025

Stephen Dewhurst, Ph.D., of the University of Rochester, R21/R33 sample application

Last Reviewed: March 31, 2025

Nico Contreras, Ph.D., of University of Arizona, F31 sample application

Last Reviewed: March 31, 2025

Lilliam Ambroggio, Ph.D., of the Cincinnati Children’s Hospital Medical Center K01 sample application

Last Reviewed: March 31, 2025

This document provides a progress report for NIAID Biodefense Research Agenda for Category B and C Priority Pathogens.

Last Reviewed: August 6, 2019

This document provides a progress report about the Biodefense Research Agenda for CDC Category A Agents in 2006.

Last Reviewed: August 6, 2019

This document outlines systematic evaluation of nine monogenic autoinflammatory diseases.

Last Reviewed: April 7, 2021

Sample application from David Al-Adra MD, Ph.D., for NIH standard independent research project grant (K08).

Last Reviewed: September 13, 2024

Lead Institution: Walter and Eliza Hall Institute of Medical Research (WEHI) Background Overall, the Asia-Pacific region has achieved impressive reductions in malaria over the last 20 years. However, the Asia-Pacific ICEMR, with funding from2017-2024, documented strongly diverging regional malaria trends: Cambodia is nearing Plasmodium falciparum elimination but is confronted with the challenge of

Last Reviewed: July 12, 2024

This document summarizes a web-based iterative analysis platform integrating pathway and network approaches.

Last Reviewed: May 4, 2021

Scientists have long been aware that malaria infection is associated with high levels of autoantibodies—antibodies that recognize and attack the person’s own tissues and are associated with autoimmune disorders. NIAID researchers, along with their colleagues, have studied the molecular mechanisms of these autoantibodies. Their findings reveal the associations between malaria, human resistance to it, and autoantibodies that are linked to certain autoimmune disorders—specifically, systemic lupus erythematosus (SLE).

Published: July 5, 2024

Sample application from Nicole Putnam, Ph.D., for National Research Service Award (NRSA) individual fellowship (F31) grants.

Last Reviewed: January 25, 2023

Office of Research on Women’s Health and NIH Support for Research on Women’s Health Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020 508-compliant PDF

Last Reviewed: March 8, 2022

The scientific community can learn about NIAID funding opportunities, programs, and networks to further research and encourage collaboration as well as resources provided by NIAID to advance product development. Recent publications and ways to connect with other researchers studying Lyme disease, Rocky Mountain Spotted Fever, and Crimean-Congo Hemorrhagic Fever are also available.

Last Reviewed: November 10, 2024

Jordan Report: Accelerated Development of Vaccines (2012) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2012

Expert articles from Jordan Report: Accelerated Development of Vaccines (2012) from NIAID

Last Reviewed: December 31, 2012

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

Jordan Report: Accelerated Development of Vaccines (2007) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: August 6, 2019

National Institutes of Health // Food and Drug Administration // Immunology Interest Group

Last Reviewed: October 6, 2022

LMIV Vaccine Development Unit develops and performs clinical evaluation of prototype malaria vaccines. The VDU focuses on research to eradicate malaria through development of a vaccine to interrupt malaria transmission, including transmission-blocking components and pre-erythrocytic components. The VDU also designs and develops vaccines specifically to protect pregnant women and their infants.

Last Reviewed: November 21, 2022